Selected article for: "abdominal pain and liver gastrointestinal"
Author: Wang, Haizhou; Qiu, Peishan; Liu, Jing; Wang, Fan; Zhao, Qiu
Title: The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: a systematic review and meta-analysis
  • Cord-id: 3knl9k68
  • Document date: 2020_5_12
    • ID: 3knl9k68
    Snippet: Abstract Backgrounds: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the association of liver injury and gastrointestinal symptoms (GIS) with the progression of COVID-19. Methods: A comprehensive search was performed on the PubMed to identify eligible studies that summarized the liver injury and GIS in COVID-19. Results: A total of 21 studies with 3024 patients were included. Up
    Document: Abstract Backgrounds: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the association of liver injury and gastrointestinal symptoms (GIS) with the progression of COVID-19. Methods: A comprehensive search was performed on the PubMed to identify eligible studies that summarized the liver injury and GIS in COVID-19. Results: A total of 21 studies with 3024 patients were included. Up to 53% patients had liver dysfunctions and the degree of liver damage was associated the severity of the disease. The prevalence of diarrhoea, nausea/vomiting or abdominal pain in patients with COVID-19 were 9.1%, 5.2% and 3.5%, respectively. No significant was found in the prevalence of diarrhoea (OR, 1.24; 95%CI, 0.90 to 1.72; I2 = 0%, p = 0.19) and nausea/vomiting (OR, 1.24; 95%CI, 0.57 to 2.69; I2 = 61%, p = 0.58) between severe and non-severe patients. In addition, diarrhoea (OR, 1.22; 95%CI, 0.50 to 2.98; I2 = 0%, p = 0.66) and nausea/vomiting (OR, 1.09; 95%CI, 0.46 to 2.62; I2 = 0%, p = 0.84) were not associated with the prognosis of COVID-19 patients. Conclusions: The incidences of GIS in patients with COVID-19 is relatively low and are not associated with the COVID-19 progression. Gastroenterologists should pay more attention to the liver injury induced by SARS-CoV-2 during the course of infection.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and liver cell: 1
    • abdominal pain and liver damage: 1, 2, 3, 4, 5, 6, 7
    • abdominal pain and liver dysfunction: 1, 2, 3, 4
    • abdominal pain and liver impairment: 1, 2, 3, 4
    • abdominal pain and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • abdominal pain and liver protection: 1
    • abdominal pain and liver protection treatment: 1
    • abdominal pain nausea vomiting and abnormal level: 1, 2, 3
    • abdominal pain nausea vomiting and liver cell: 1
    • abdominal pain nausea vomiting and liver damage: 1, 2, 3, 4, 5
    • abdominal pain nausea vomiting and liver dysfunction: 1, 2
    • abdominal pain nausea vomiting and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • abdominal pain nausea vomiting diarrhoea prevalence and liver injury: 1
    • abdominal pain vomiting and abnormal level: 1, 2, 3
    • abdominal pain vomiting and liver cell: 1
    • abdominal pain vomiting and liver damage: 1, 2, 3, 4, 5
    • abdominal pain vomiting and liver dysfunction: 1, 2, 3
    • abdominal pain vomiting and liver impairment: 1, 2
    • abdominal pain vomiting and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16